A French pharmaceutical company is specialized in developing innovative treatments for diseases of the nervous system with high unmet medical needs. Within the frame of its development as fully integrated pharmaceutical company, it is currently looking for new assets for its portfolio in the field of neurological disorders. This company is considering license and/or research cooperation agreement as well as joint-venture agreement.
A French pharmaceutical company specialized in neurological diseases with high unmet medical needs. Its core focus lies on the metabolic alterations of central nervous system diseases as novel therapeutic approach.
The company's pipeline is currently composed of one molecule that has successfully finished phase III, two further compounds in late preclinical development and they have their own research platform to identify further promising therapeutic targets.
Within the frame of their development as fully integrated pharmaceutical company, it is now looking for new assets for the extension of its portfolio in the field of central nervous system disorders with high unmet medical needs. It is interested in new best- or first-in-class assets (new chemical entity, biologicals, repurposed drugs) preferentially targeting brain metabolism from early developmental stages (drug discovery) to late clinical phases. With its track record of successfully developed molecules and its expertise to progress the development of drugs from discovery to commercialisation, it is able to provide new treatment solutions for patients in need.
The French company is flexible concerning deal structure and is opened to different types of partnerships including in-licensing, co-development, research and development collaboration or sponsored research with both industrial and academic partners.
- Type of partner sought: Research institutes, hospital or biotechnological and pharmaceutical companies with therapeutic assets that are looking for a partner to develop the molecules through preclinical and clinical stages towards commercialisation.
- Specific area of activity of the partner: Industrial and academic partners, open for licensing, co-development, sponsored research with a pharmaceutical company
02/04/2019 - UK Funding for Innovation
04/06/2019 - Future of Building 2019